Press Release

SAN FRANCISCO, CA – February 24, 2021 – Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera“) today provided the following corporate update at the request of the TSX Venture Exchange (“TSXV”) ahead of the reinstatement…

SAN FRANCISCO, CA — (January 22, 2021) – Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today announces that its previously announced cease trade order has been revoked. On June 22, 2020, the British Columbia Securities…

SAN FRANCISCO, CA and TORONTO, ON — (January 12, 2021) – Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today provided the following information to bring shareholders up to date with respect of its activities. As previously announced,…

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that Kost Forer Gabbay & Kasierer/Ernst & Young Global (“E&Y”) have, at the request of the Company, resigned as auditors of the Company, effective August...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided the following updates regarding recent and ongoing activities. Private Placement As previously announced on July 24, 2020, the Company closed in escrow it’s previously announced...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that on and effective July 22, 2020 it has closed in escrow its previously announced non-brokered private placement (the “Private Placement”) of units comprised of...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a License Agreement (the “License Agreement”) with Salzman Group, Inc. (“Salzman Group”), under which Salzman Group has granted to Kalytera...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announces that it has received conditional approval from the TSX Venture Exchange ("TSXV”) and partial revocation orders from the British Columbia and Ontario Securities Commissions granted today...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending December 31, 2019 and the...

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (the “Acquisition”). On May 19, 2020, Kalytera announced...